vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Terreno Realty Corp (TRNO). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $137.5M, roughly 1.4× Terreno Realty Corp). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 32.6%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 27.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Terreno Realty Corp is a publicly traded real estate investment trust that specializes in owning, operating, and acquiring high-quality industrial real estate assets. Its portfolio mainly includes distribution warehouses and logistics facilities located in high-demand coastal U.S. metropolitan markets, serving tenants across e-commerce, last-mile delivery, retail supply chain, and light manufacturing segments.
AXSM vs TRNO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $137.5M |
| Net Profit | — | $158.2M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 115.1% |
| Revenue YoY | 57.4% | 32.6% |
| Net Profit YoY | — | 107.9% |
| EPS (diluted) | — | $1.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $137.5M | ||
| Q3 25 | $171.0M | $116.2M | ||
| Q2 25 | $150.0M | $112.2M | ||
| Q1 25 | $121.5M | $110.4M | ||
| Q4 24 | $118.8M | $103.7M | ||
| Q3 24 | $104.8M | $99.6M | ||
| Q2 24 | $87.2M | $94.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $158.2M | ||
| Q3 25 | $-47.2M | $103.4M | ||
| Q2 25 | $-48.0M | $93.3M | ||
| Q1 25 | $-59.4M | $48.1M | ||
| Q4 24 | $-74.9M | $76.1M | ||
| Q3 24 | $-64.6M | $36.6M | ||
| Q2 24 | $-79.3M | $35.7M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 115.1% | ||
| Q3 25 | -27.6% | 88.9% | ||
| Q2 25 | -32.0% | 83.1% | ||
| Q1 25 | -48.9% | 43.6% | ||
| Q4 24 | -63.1% | 73.4% | ||
| Q3 24 | -61.7% | 36.8% | ||
| Q2 24 | -91.0% | 37.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $1.54 | ||
| Q3 25 | $-0.94 | $1.00 | ||
| Q2 25 | $-0.97 | $0.90 | ||
| Q1 25 | $-1.22 | $0.47 | ||
| Q4 24 | $-1.54 | $0.78 | ||
| Q3 24 | $-1.34 | $0.37 | ||
| Q2 24 | $-1.67 | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $25.0M |
| Total DebtLower is stronger | $70.0M | $943.3M |
| Stockholders' EquityBook value | — | $4.1B |
| Total Assets | $713.6M | $5.4B |
| Debt / EquityLower = less leverage | — | 0.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $25.0M | ||
| Q3 25 | $325.3M | $26.2M | ||
| Q2 25 | $303.0M | $128.4M | ||
| Q1 25 | $300.9M | $156.5M | ||
| Q4 24 | $315.4M | $18.1M | ||
| Q3 24 | $327.3M | $243.7M | ||
| Q2 24 | $315.7M | $182.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $943.3M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $742.4M | ||
| Q1 25 | — | $741.9M | ||
| Q4 24 | — | $823.4M | ||
| Q3 24 | — | $672.2M | ||
| Q2 24 | — | $772.0M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $4.1B | ||
| Q3 25 | $73.7M | $4.0B | ||
| Q2 25 | $73.1M | $3.9B | ||
| Q1 25 | $53.2M | $3.9B | ||
| Q4 24 | $57.0M | $3.7B | ||
| Q3 24 | $92.9M | $3.6B | ||
| Q2 24 | $102.9M | $3.4B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $5.4B | ||
| Q3 25 | $669.3M | $5.3B | ||
| Q2 25 | $639.8M | $5.0B | ||
| Q1 25 | $596.7M | $4.9B | ||
| Q4 24 | $568.5M | $4.8B | ||
| Q3 24 | $561.5M | $4.6B | ||
| Q2 24 | $548.2M | $4.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $271.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $271.9M | ||
| Q3 25 | $1.0M | $79.5M | ||
| Q2 25 | $-32.4M | $60.6M | ||
| Q1 25 | $-43.4M | $61.4M | ||
| Q4 24 | $-26.2M | $232.7M | ||
| Q3 24 | $-18.6M | $70.0M | ||
| Q2 24 | $-30.1M | $64.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | 1.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TRNO
| Disposal Group Disposed Of By Sale Not Discontinued Operations | $109.5M | 80% |
| Other | $23.8M | 17% |
| At Market Equity Offering Program500Million | $4.1M | 3% |
